Hartford HealthCare has announced a new collaboration with an Israel-based medical technology startup to use AI technology to help doctors with cancer diagnosis and improve care for breast cancer patients.
The partnership is with Medical Analytics, which provides artificial intelligence-backed cancer diagnostics technology and will deploy its AI service called Galen Breast, which helps pathologists detect and grade different types of invasive and noninvasive breast cancer.
There are more than 2 million new cases of breast cancer in the U.S. annually and about one in eight American women are expected to develop invasive breast cancer, according to the Hartford-based healthcare system.
Dr. Margaret Assad, program director of the selective pathology fellowship at Hartford Hospital, said HHC pathologists could use Galen Breast to analyze all cases of breast cancer after reviewing slides under a microscope.
“This AI assistant provides a higher safety net with minimal, additional effort,” Assad said in a statement.
Officials at Ibex, which has offices in Israel and Brookline, Mass., applauded the new arrangement with HHC, which was officially announced Monday morning.
“We are proud to partner with Hartford Healthcare to support their ongoing digital transformation,” said Ibex Chief Revenue Officer Joel Duckworth. “With Ibex’s trusted AI and advanced digital pathology technologies, Hartford Healthcare can empower their pathologists to deliver highly accurate and prompt diagnoses, with the potential to directly impact prognosis for patients, setting a new standard in breast cancer care quality in the United States.”
HHC has more than 400 locations, serving more than 17,000 people.
